Literature DB >> 5310206

Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculous patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone.

S Devadatta, J J Dawson, W Fox, B Janardhanam, S Radhakrishna, C V Ramakrishnan, S Velu.   

Abstract

This report from the Tuberculosis Chemotherapy Centre, Madras, considers the risk, over a 5-year period, to close family contacts of sputum-positive patients treated at home for 1 year with a standard regimen of isoniazid plus PAS or one of 3 regimens of isoniazid alone. The attack rate of tuberculosis in the contacts did not appear to be influenced by the treatment received by the patients in the first year or by the duration in the 5-year period for which the patients had (1) positive sputum smears, (2) positive cultures, or (3) isoniazid-resistant cultures. Further, over half the cases of tuberculosis developed in the first year, many of these being in the first 3 months. These findings confirm the conclusions reached from an earlier study, namely, that the major risk to the contacts is from exposure to the infectious patient before diagnosis, and that the risks from the other possible sources of infection (the patient during treatment and the urban environment of Madras) are, in comparison, small.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5310206      PMCID: PMC2427525     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  19 in total

1.  UNITED STATES PUBLIC HEALTH SERVICE TRIALS OF ISONIAZID PROPHYLAXIS.

Authors:  S H FEREBEE
Journal:  Bull Int Union Tuberc       Date:  1964-09

2.  Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.

Authors:  S H FEREBEE; F W MOUNT
Journal:  Am Rev Respir Dis       Date:  1962-04

3.  Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs and mice.

Authors:  M BARNETT; S R BUSBY; D A MITCHISON
Journal:  Br J Exp Pathol       Date:  1953-10

4.  Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

Authors:  G MIDDLEBROOK; M L COHN
Journal:  Science       Date:  1953-09-11       Impact factor: 47.728

5.  ISONIAZID-RESISTANT strains of Mycobacterium tuberculosis.

Authors: 
Journal:  Lancet       Date:  1953-05-16       Impact factor: 79.321

6.  Spread of drug-resistant tubercle bacilli.

Authors:  E Brander; K Aho; J Pätiälä
Journal:  Am Rev Respir Dis       Date:  1968-09

7.  Intermittent chemotherapy with isoniazid and streptomycin in Algiers.

Authors:  P Chaulet; D Larbaoui; J Grosset; K Abderrahim
Journal:  Tubercle       Date:  1967-06

8.  Diluents for stabilization of tuberculin.

Authors:  M MAGNUSSON; J GULD; K MAGNUS; H WAALER
Journal:  Bull World Health Organ       Date:  1958       Impact factor: 9.408

9.  A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India.

Authors:  S R Kamat; J J Dawson; S Devadatta; W Fox; B Janardhanam; S Radhakrishna; C V Ramakrishnan; P R Somasundaram; H Stott; S Velu
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

10.  A 5-year study of patients with pulmonary tuberculosis treated at home in a controlled comparison of isoniazid plus PAS with 3 regimens of isoniazid alone.

Authors:  C Evans; S Devadatta; W Fox; P R Gangadharam; N K Menon; C V Ramakrishnan; S Sivasubramanian; P R Somasundaram; H Stott; S Velu
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  11 in total

Review 1.  Tuberculosis--chemotherapy.

Authors:  K M Citron
Journal:  Br Med J       Date:  1972-02-12

Review 2.  Chemotherapy of tuberculosis in children.

Authors:  P Ramachandran
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

3.  Transmission of tuberculosis to contacts of sputum positive adults in Malawi.

Authors:  J M Topley; D Maher; L N Mbewe
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

4.  Multivariate Markovian modeling of tuberculosis: forecast for the United States.

Authors:  S M Debanne; R A Bielefeld; G M Cauthen; T M Daniel; D Y Rowland
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

Review 5.  Contact investigation for tuberculosis: a systematic review and meta-analysis.

Authors:  Gregory J Fox; Simone E Barry; Warwick J Britton; Guy B Marks
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

Review 6.  Immunological basis of early clearance of Mycobacterium tuberculosis infection: the role of natural killer cells.

Authors:  F Abebe
Journal:  Clin Exp Immunol       Date:  2021-01-05       Impact factor: 5.732

Review 7.  Genetic Resistance to Mycobacterium tuberculosis Infection and Disease.

Authors:  Marlo Möller; Craig J Kinnear; Marianna Orlova; Elouise E Kroon; Paul D van Helden; Erwin Schurr; Eileen G Hoal
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

8.  Risk factors for tuberculosis.

Authors:  Padmanesan Narasimhan; James Wood; Chandini Raina Macintyre; Dilip Mathai
Journal:  Pulm Med       Date:  2013-02-12

Review 9.  Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection.

Authors:  Jason D Simmons; Catherine M Stein; Chetan Seshadri; Monica Campo; Galit Alter; Sarah Fortune; Erwin Schurr; Robert S Wallis; Gavin Churchyard; Harriet Mayanja-Kizza; W Henry Boom; Thomas R Hawn
Journal:  Nat Rev Immunol       Date:  2018-09       Impact factor: 108.555

10.  IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure.

Authors:  Chetan Seshadri; Galit Alter; Lenette L Lu; Malisa T Smith; Krystle K Q Yu; Corinne Luedemann; Todd J Suscovich; Patricia S Grace; Adam Cain; Wen Han Yu; Tanya R McKitrick; Douglas Lauffenburger; Richard D Cummings; Harriet Mayanja-Kizza; Thomas R Hawn; W Henry Boom; Catherine M Stein; Sarah M Fortune
Journal:  Nat Med       Date:  2019-05-20       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.